Get the Stockscreener App
154.96
1.46%
2.205
Charles River Laboratories International Inc stock is traded at $154.96, with a volume of 1.35M.
It is up +1.46% in the last 24 hours and down -2.77% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$152.75
Open:
$153.34
24h Volume:
1.35M
Relative Volume:
1.48
Market Cap:
$7.63B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
19.35
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
+3.09%
1M Performance:
-2.77%
6M Performance:
+1.18%
1Y Performance:
-23.84%
1-Day Range:
$151.56
$155.26
1-Week Range:
$145.99
$155.26
52-Week Range:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
154.94 | 7.33B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
485.15 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
208.42 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.54 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.07 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
189.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Do Charles River (CRL) Earnings Trends Reveal Shifting Priorities in Its Advanced Therapeutics Ambitions? - simplywall.st
5 Revealing Analyst Questions From Charles River Laboratories’s Q2 Earnings Call - Yahoo Finance
Stock Analysis | Charles River Laboratories International OutlookMixed Technical Signals and Strong Fundamentals - AInvest
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - Yahoo Finance
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View - MSN
Interpreting Charles River (CRL) International Revenue Trends - Yahoo Finance
Charles River Laboratories International Inc. Recovery Linked to Earnings SurprisePattern Alert With ROI Driven Strategy Shared - metal.it
Charles River Laboratories Q2 2025 Earnings Call Transcript Summary - AInvest
Charles River Laboratories International Inc's Q2 2025 Financials and Strategic Direction: A SWOT Analysis - AInvest
Charles River Laboratories Reports Q2 2025 Earnings - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MSN
Charles River Laboratories International 2025 Q2 Earnings Misses Targets as Net Income Drops 44% - AInvest
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript - Insider Monkey
Charles River Laboratories International Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Charles River Laboratories Q2 2025 Earnings Preview - MSN
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionWeekly Hot Picks With Buy Confidence Released - beatles.ru
Charles River Laboratories International Q2 2025 Earnings Call Transcript - MarketBeat
Charles River Laboratories International 2025 Q2 Earnings Beats Expectations as Net Income Drops 44.1% - AInvest
Charles River: Q2 Earnings Snapshot - Milford Mirror
Charles River Labs Reports Mixed Q2 Earnings Call - TipRanks
Charles River Laboratories Shares Drop 10.25% Despite 49.73% Volume Surge Ranking 339th in Market Activity as Order Cancellations Weigh on Investor Sentiment - AInvest
Charles River (CRL) Q2 EPS Jumps 11% - The Globe and Mail
Charles River (CRL) Q2 EPS Jumps 11% - The Motley Fool
Charles River Labs stock price target raised to $175 by BofA Securities - Investing.com India
Charles River Laboratories Q2 2025 Earnings Call Transcript Review - AInvest
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Benzinga
Charles River: Margin Fears Outweigh Solid Q2 (NYSE:CRL) - Seeking Alpha
Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $185 From $180 - MarketScreener
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2 - Yahoo Finance
Charles River Labs Q2 2025 slides: Beats expectations, raises guidance amid stabilizing demand - Investing.com Canada
Charles River Laboratories Announces Second-Quarter 2025 Results - BioSpace
Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Updated - MarketScreener
Charles River Laboratories Reports Q2 2025 Revenue of $1.03 Bill - GuruFocus
Charles River Labs soars 6.9% after crushing Q2 earnings expectations By Investing.com - Investing.com South Africa
Charles River Labs soars 6.9% after crushing Q2 earnings expectations - Investing.com
Charles River Laboratories earnings beat by $0.62, revenue topped estimates - Investing.com Canada
Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
How volatile is Charles River Laboratories International Inc. stock compared to the marketBuild wealth steadily with proven strategies - Jammu Links News
Charles River Laboratories International Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - Jammu Links News
What is Charles River Laboratories International Inc. company’s growth strategyBuild a winning investment portfolio - Jammu Links News
Is it the right time to buy Charles River Laboratories International Inc. stockIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Charles River Laboratories International Inc. stockRobust investment performance - Jammu Links News
How strong is Charles River Laboratories International Inc. company’s balance sheetMarket-leading profit generation - Jammu Links News
What are Charles River Laboratories International Inc. company’s key revenue driversAchieve breakthrough gains with expert advice - Jammu Links News
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.19%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):